Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
73 hedge funds and large institutions have $43.2M invested in Catalyst Pharmaceutical in 2016 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 25 increasing their positions, 18 reducing their positions, and 21 closing their positions.
39% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 18
6.42% less ownership
Funds ownership: 51.05% → 44.62% (-6.4%)
14% less funds holding
Funds holding: 85 → 73 (-12)
57% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 21
58% less capital inflows, than outflows
Capital inflows: $10.7M | Capital outflows: $25.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Broadfin Capital
New York
|
+$6.23M |
| 2 |
Tanaka Capital Management
New York
|
+$884K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$818K |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$789K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
+$298K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Consonance Capital Management
New York
|
-$7.08M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$5.21M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$4.31M |
| 4 |
Allianz Asset Management
Munich,
Germany
|
-$2.01M |
| 5 |
Perceptive Advisors
New York
|
-$1.24M |
CPRX Hedge Fund Activity: Q1 2016 in Review
73 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q1 2016, worth a combined $43.2M — down 58% from $104M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of CPRX and 9 opened new positions — a net loss of 12 holders — while 18 trimmed existing stakes and 25 added.
The largest buyer was Broadfin Capital, adding an estimated $6.23M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $7.08M sold.
- 73 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q1 2016, down from 85 in Q4 2015.
- Funds reported $43.2M of Catalyst Pharmaceutical stock for Q1 2016, down 58% quarter-over-quarter.
- 9 funds opened new Catalyst Pharmaceutical positions in Q1 2016 and 21 closed out, a net change of -12 holders.
- The largest Catalyst Pharmaceutical buyer in Q1 2016 was Broadfin Capital, an estimated $6.23M added.
- The largest Catalyst Pharmaceutical seller in Q1 2016 was Consonance Capital Management, an estimated $7.08M sold.
Based on aggregated 13F filings for Q1 2016.